Figures & data
Table 1 Main types of antiretroviral treatment regimens initiated in switches to a more economical regimen in individuals with suppressed plasma HIV-1 RNA (<50 copies/mL)
Table 2 Different categories of switches in antiretroviral treatment undertaken in a cohort of 2401 HIV-1-infected patients during the study period
Figure 1 Correlation between the number of switches identified as cost-saving measures and the costs saved with them (shown as percentages).
![Figure 1 Correlation between the number of switches identified as cost-saving measures and the costs saved with them (shown as percentages).](/cms/asset/0cd49418-1fe6-4534-b117-c2fa02ccd5d6/dceo_a_43662_f0001_b.jpg)
Table 3 Comparison of the number of cost-reduction measures undertaken (shown as categories) and costs saved with each one
Figure 2 Final savings achieved during the study period with the three main cost-saving strategies: cost-effective treatment changes, inclusion in antiretroviral treatment trials (with antiretroviral medication totally or partially paid for by the sponsor of the clinical trial), and discount arrangements (shown as € per month saved).
![Figure 2 Final savings achieved during the study period with the three main cost-saving strategies: cost-effective treatment changes, inclusion in antiretroviral treatment trials (with antiretroviral medication totally or partially paid for by the sponsor of the clinical trial), and discount arrangements (shown as € per month saved).](/cms/asset/455ba83d-5718-4d52-806e-45229df75158/dceo_a_43662_f0002_b.jpg)